Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Bellevue, WA
A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Bellevue, WA
Click here to add this to my saved trials
A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Seattle, WA
A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Kenosha, WI
A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Kenosha, WI
Click here to add this to my saved trials
A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Mount Pleasant, SC
A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated:  12/8/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis
Status: Enrolling
Updated: 12/8/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Neuroplasticity Technology for Attention-deficit/Hyperactivity Disorder (ADHD)
Neuroplasticity Technology for Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  12/10/2017
Boston Children's Hospital
mi
from
Boston, MA
Neuroplasticity Technology for Attention-deficit/Hyperactivity Disorder (ADHD)
Neuroplasticity Technology for Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 12/10/2017
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Status: Enrolling
Updated:  12/11/2017
UCLA
mi
from
Los Angeles, CA
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Status: Enrolling
Updated: 12/11/2017
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Status: Enrolling
Updated:  12/11/2017
Northwestern University
mi
from
Evanston, IL
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Status: Enrolling
Updated: 12/11/2017
Northwestern University
mi
from
Evanston, IL
Click here to add this to my saved trials
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Status: Enrolling
Updated:  12/11/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Status: Enrolling
Updated: 12/11/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Status: Enrolling
Updated:  12/11/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Status: Enrolling
Updated: 12/11/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
UC Davis Medical Center
mi
from
Sacramento, CA
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
UC Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Children's Hospital Colorado Center for Cancer and Blood Disorders
mi
from
Aurora, CO
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Children's Hospital Colorado Center for Cancer and Blood Disorders
mi
from
Aurora, CO
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Child Neurology Center of Northwest Florida
mi
from
Gulf Breeze, FL
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Child Neurology Center of Northwest Florida
mi
from
Gulf Breeze, FL
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Rush University Medical Center
mi
from
Chicago, IL
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
University of Iowa
mi
from
Iowa City, IA
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Boston Children's Hospital
mi
from
Boston, MA
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Washington University School of Medicine, Division of Endocrinology, Metabolism and Lipid Research
mi
from
Saint Louis, MO
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Washington University School of Medicine, Division of Endocrinology, Metabolism and Lipid Research
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Columbia University College of Physicians and Surgeons
mi
from
New York, NY
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Columbia University College of Physicians and Surgeons
mi
from
New York, NY
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Nationwide Children's Hospital
mi
from
Columbus, OH
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Oregon Health and Science University
mi
from
Portland, OR
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Childrens Medical Center Dallas, Texas
mi
from
Dallas, TX
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Childrens Medical Center Dallas, Texas
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Texas Children's Hospital
mi
from
Houston, TX
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
University of Utah
mi
from
Salt Lake City, UT
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Seattle Children's Hospital - Childhood Cancer and Blood Disorders
mi
from
Seattle, WA
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Seattle Children's Hospital - Childhood Cancer and Blood Disorders
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Children's Hospital Boston
mi
from
Boston, MA
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated:  12/11/2017
Children's Hospital at Westmead
mi
from
Westmead,
Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy
A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
Status: Enrolling
Updated: 12/11/2017
Children's Hospital at Westmead
mi
from
Westmead,
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Arizona Oncology Services Foundation
mi
from
Phoenix, AZ
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Arizona Oncology Services Foundation
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Rebecca and John Moores UCSD Cancer Center
mi
from
La Jolla, CA
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Rebecca and John Moores UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
mi
from
Orange, CA
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Aurora Presbyterian Hospital
mi
from
Aurora, CO
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Aurora Presbyterian Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
St. Anthony Central Hospital
mi
from
Denver, CO
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
St. Anthony Central Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Porter Adventist Hospital
mi
from
Denver, CO
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Presbyterian - St. Luke's Medical Center
mi
from
Denver, CO
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Presbyterian - St. Luke's Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
St. Joseph Hospital
mi
from
Denver, CO
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
St. Joseph Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
CCOP - Colorado Cancer Research Program, Inc.
mi
from
Denver, CO
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
CCOP - Colorado Cancer Research Program, Inc.
mi
from
Denver, CO
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Swedish Medical Center
mi
from
Englewood, CO
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Swedish Medical Center
mi
from
Englewood, CO
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Eastern Connecticut Hematology and Oncology Associates
mi
from
Norwich, CT
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Eastern Connecticut Hematology and Oncology Associates
mi
from
Norwich, CT
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Florida Hospital Cancer Institute at Florida Hospital Orlando
mi
from
Orlando, FL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Florida Hospital Cancer Institute at Florida Hospital Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated:  12/12/2017
Illinois CancerCare-Bloomington
mi
from
Bloomington, IL
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
Phase III Study of Radiation Therapy With or Without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Status: Enrolling
Updated: 12/12/2017
Illinois CancerCare-Bloomington
mi
from
Bloomington, IL
Click here to add this to my saved trials